AUTOTEC: Preparation of Radiopharmaceuticals by Automaton: Operators Dosimetry

Sponsor
Central Hospital, Nancy, France (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT03974256
Collaborator
(none)
22
1
2
30
0.7

Study Details

Study Description

Brief Summary

The radiopharmaceuticals manipulation used in nuclear medicine department is a significant source of radiation for operators.

According to Article R. 4451-13 of the Labor Code, the exposure limit for hands and skin (average dose over a surface of 1 cm²) received during twelve consecutive months can't exceed the annual dose limit 500 millisieverts (mSv).

The radiopharmaceuticals manipulation exposes operators to the risk of exceeding this limit, as has been shown in a European study.

At present, there are automatons on the market but only for radiopharmaceutical fluorodeoxyglucose (FDG).

One of the advantages of such an automaton is to reduce irradiation of operators' hands during the radiopharmaceuticals preparation. This reduction can reach 95% according to certain authors and the type of automaton.

This study therefore proposes to evaluate the effect of an original, newly designed automaton on operators' dosimetry and the labelled radiopharmaceuticals' quality.

The hypothesis emitted in this study is that the use of this automaton would allow to reduce drastically operators' hands exposure and probably also to improve the precision of the prepared syringes.

This study will be done in a paired way, require a randomization in cross-over and each of the subjects included will be its own witness.

Condition or Disease Intervention/Treatment Phase
  • Other: Training in the use of the automaton
N/A

Detailed Description

Currently, radiopharmaceuticals for diagnostic purposes are prepared by operators, Technologist in Medical Electro-Radiology or/and Pharmacy Technicians, manually for radiopharmaceuticals labelled with Technetium-99m (99mTc), or using an automaton for radiopharmaceuticals FDG.

At present, there are automatons on the market but only for radiopharmaceuticals FDG.

However, these automatons are currently only used to split into individual doses radiopharmaceuticals FDG, the labelling radiopharmaceuticals being carried out before delivery in nuclear medicine departments.

The Sysark SAS's company has created and patented, with the collaboration of the Center of Research in Automatic Control of Nancy (CRAN, mixed unite of research 7039 common to the University of Lorraine and the CNRS) an innovative automaton for the preparation of radiopharmaceuticals labelled with 99mTc, used to perform scintigraphy examinations of nuclear medicine department.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
22 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Intervention Model Description:
Interventional study, multicenter, randomized, cross-over, open, at risk and minimal constraintsInterventional study, multicenter, randomized, cross-over, open, at risk and minimal constraints
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
Evaluation of a New Strategy for the Preparation of Technetium Radioactive Medicaments Using an Innovative Automaton for Nuclear Medicine Examinations: Impact on the Dosimetry of Operators and on the Quality of Preparations
Anticipated Study Start Date :
Jan 1, 2022
Anticipated Primary Completion Date :
Jan 1, 2023
Anticipated Study Completion Date :
Jul 1, 2024

Arms and Interventions

Arm Intervention/Treatment
No Intervention: Group standard method

Operators work during 4 days with thermoluminescent dosimeters (TLD), according to the conventional manual method of preparation of technetium-99m labelled radioactive medicinal products for diagnostic according with good preparation practices and the recommendations contained in the summary of characteristics

Experimental: Group automated method

Operators work during 4 days with TLD, according to the automated method of preparation of technetium-99m labelled radioactive medicinal products for diagnostic according with good preparation practices and the recommendations contained in the summary of characteristics

Other: Training in the use of the automaton
2 days training on automaton use

Outcome Measures

Primary Outcome Measures

  1. Total radiopharmaceutical activity prepared in mega-becquerel (MBq) [Throughout 4 working days of each methods]

    For each of the two methods of preparation

  2. Number of days of handling [Throughout 4 working days of each methods]

    For each of the two methods of preparation

Secondary Outcome Measures

  1. Accuracy in terms of activity (MBq) of prepared syringes, expressed as a percentage (%) of the prescribed target value, and compared between the automated device and the conventional manual method [Throughout 4 working days of each methods]

    For each of the two methods of preparation

  2. A likert of 4 modalities will be used to evaluate the level of comfort in the automaton by operators (from "Very uncomfortable" to "Very comfortable") [After 4 working days of this method]

    During the automated method of preparation

  3. A likert of 4 modalities will be used to evaluate the confidence level in the automaton by operators (from "Not at all confident" to "Totally confident") [After 4 working days of each methods]

    During the automated method of preparation

  4. Level of operators' irradiation, measured by the breast dosimeter during the 4 days of preparation (in µSv) and expressed in relation to the total radiopharmaceuticals' activity prepared during the same period (in MBq) [Throughout 4 working days of each methods]

    For each of the two methods of preparations

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Adult (age > 18 years)

  • Operators: Technologist in Electro-Radiology Medical / Pharmacy Technician

  • Operators experienced and autonomous in labelling radiopharmaceuticals with technetium-99m, at least one year

  • Operators having agreed to participate in the study, having received complete information on the organization of the research and having signed a free and informed consent

  • Operators affiliated to a social security scheme or beneficiary of such a scheme

Exclusion Criteria:
  • A woman of childbearing age who doesn't have effective contraception

  • Persons referred in Articles L. 1121-5, L 1121-8 of the French Public Health Code:

  • Pregnant woman, parturient or mother who is breastfeeding

  • Chil (not emancipated)

  • Adult subject to a measure of legal protection (guardianship, curators, safeguard of justice)

  • Adult unable to express consent

  • Persons deprived of their liberty by a judicial or administrative decision, persons under psychiatric care pursuant to Articles L. 3212-1 and L. 3213-1

Contacts and Locations

Locations

Site City State Country Postal Code
1 CHRU Nancy - Brabois Vandoeuvre-les-Nancy France 54511

Sponsors and Collaborators

  • Central Hospital, Nancy, France

Investigators

  • Principal Investigator: Rachel GRIGNON, Technologist, GIE NANCYCLOTEP

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Central Hospital, Nancy, France
ClinicalTrials.gov Identifier:
NCT03974256
Other Study ID Numbers:
  • PHRIP2018/AUTOTEC-GRIGNON-AS
First Posted:
Jun 4, 2019
Last Update Posted:
Aug 5, 2021
Last Verified:
Aug 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Central Hospital, Nancy, France

Study Results

No Results Posted as of Aug 5, 2021